SLC5A2 and heart failure: A meta-analysis including EMPA-REG OUTCOME (empagliflozin), CANVAS Program (canagliflozin), DECLARE-TIMI 58 (dapagliflozin), CREDENCE (canagliflozin) and VERTIS CV (ertugliflozin) demonstrated that SGLT2 inhibitors reduced MACE by 10% (hazard ratio [HR] 0.90, 95% confidence interval [CI] 0.85–0.95) and hospitalization for heart failure by 32% (HR 0.68, 95% CI 0.61–0.76) compared to placebo [6].